A friend of mine called me and he recommended CASI. I know my friend is connected to some other investors who are very sharp and alert on investments. I told him that you better buy SPPI which owns 20% of CASI and also SPPI CEO is a board member of CASI. After all, CASI shares are not liquid at this time while with SPPI you have more flexeblities.
For 2015, there is only one payment about $6 mil in contrast to what SPPI paid in 2014.
I think, SPPI already decided to slow down on spending and put money on projects that will generate cash in shorter time. SPPI will be cash flow positive in 2015 and it may increase its cash position while focusing on some important projects.
That will bring the subject of current debt and bondholders that are acting very negatively. SPPI may start to shave the debt or find another alternative to deal with it.
Only 2 weeks left from Q1 2015. Fusilev should generate over $30 million and Q1 rev should be between $50 to $55 m. In addition, Q1 should be positive non-gap and positive cash flow based on what we saw in Q4 2014.
In December 2011, I bought PCYC at $12 and then at $15 in Jan 2012. I sold it when it reached my target price around $50 but I kept a small amount of shares.
Recently, ABBV has acquired PCYC for $21B at $261 per share. PCYC has only one cancer drug that has been approved recently. May be I can try my chance again with SPPI.
Imagine SPPI with zero rev and without any drug excerpt SPI-2012 in phase III. With those conditions, the company worth over $1B and over $15 per share. You do the math when other conditions are added.
The negative analysts cannot see more than a month in future and how can they dare to poison the market with something they are not familiar with.
If one or two analysts do not understand the potential of the drug and all the drugs in PCYC pipeline, it is their problem. Some idiots were saying the same thing when GILD bought its HEP C drug.
Analysts are focusing on one drug but ignoring the PCYC pipeline, more indication of the drug and the most important, the intellectual property that ABBV will get. They will create much more blockbusters.
It is good time to reduce the shares now, it will pay off in future.
FITB has a good size but an acquisition also makes sense.
Is this the first time you play the market? So, let me tell you a simple fact about stocks. They drop very hard on bad news but recover slowly with good news.
GILD will recover but investors are scared from the market as today but they step in slowly or sell other stocks to gather cash to buy GILD. This process takes some times and that is the reason that GILD does not go up by 10% in one day but it will takes a few days to fully recover.
So, you think you know better than GILD management and their advisers. Send them your resume and also tell us what have you managed with any success in the past so we can see the light. If not then talk-is-cheap.
Not only Horvoni clinical data is superior but also it is a single pill peer day while Viekire requires 4-6 pills with dosing more than once daily.
2- easier compliance
3- much less side effect
4- most patients qualify
Which public are you talking about? ML misled that public who are weak hands and in doubt like yourself. Short sellers took advantage of that public. Now, the reality will come back to them. The weak hands have been manipulated andd GILD will recover as it has been so far by 8% from its low of $86. After all, new investors benefited, shorts benefited, and weak hand who exited at lows lost their money.
ABBV is one of the worst stock with very blink future. ABT investors were worry about HUMIRA in 2013. Eventually, ABT came with a solution to spun off ABBV at low cost while keeping most tangible assets. HUMIRA was the only product that produced huge revenue but it will be gone in a year or so. Poor ABBV investors have to see a huge price drop as soon as the first generic Humira is applied. The ABBV hep c is the last chance to keep some investors but GILD is not a tigger paper. GILD hep c drug are superior and poor ABBV has to come up with something else before its drug becomes obsolete like Vertex INCIVEK.